Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bio Essence (BIOE) Total Liabilities (2020 - 2025)

Historic Total Liabilities for Bio Essence (BIOE) over the last 6 years, with Q3 2025 value amounting to $3.3 million.

  • Bio Essence's Total Liabilities fell 1014.32% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year decrease of 1014.32%. This contributed to the annual value of $3.3 million for FY2024, which is 2644.93% down from last year.
  • Latest data reveals that Bio Essence reported Total Liabilities of $3.3 million as of Q3 2025, which was down 1014.32% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, Bio Essence's Total Liabilities registered a high of $5.0 million during Q1 2023, and its lowest value of $2.6 million during Q2 2023.
  • Over the past 5 years, Bio Essence's median Total Liabilities value was $3.8 million (recorded in 2024), while the average stood at $3.9 million.
  • As far as peak fluctuations go, Bio Essence's Total Liabilities surged by 19014.82% in 2021, and later tumbled by 4168.78% in 2023.
  • Quarter analysis of 5 years shows Bio Essence's Total Liabilities stood at $4.1 million in 2021, then increased by 15.94% to $4.8 million in 2022, then dropped by 7.67% to $4.4 million in 2023, then fell by 26.45% to $3.3 million in 2024, then increased by 1.12% to $3.3 million in 2025.
  • Its last three reported values are $3.3 million in Q3 2025, $3.2 million for Q2 2025, and $3.5 million during Q1 2025.